EGFR and lung adenocarcinoma: Except for CREB, the cAMP/PKA-regulated phosphoprotein DARPP-32 enhances ERBB3/EGFR heterodimerization and promotes EGFR inhibitor resistance in EGFR-mutated lung adenocarcinoma [98].